Medigene AG Stock
Medigene AG Stock
Pros and Cons of Medigene AG in the next few years
Pros
Cons
Performance of Medigene AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medigene AG | -3.450% | -20.833% | -35.319% | -14.124% | -4.403% | -62.699% | -83.195% |
| Formycon AG | 0.760% | 3.516% | -12.541% | -44.014% | -28.763% | -40.405% | 11.972% |
| MagForce AG | - | 0.000% | 25.000% | -9.091% | 150.000% | -99.950% | -99.957% |
| Biofrontera AG | -7.780% | 8.280% | 0.890% | -71.064% | -16.462% | -85.892% | -94.745% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Medigene, a biotechnology and medical research firm, it is evident that the company has experienced some fluctuations in its financial position over the last few years. The balance sheets, cash flow statements, and income statements for the years 2020, 2021, and 2022 reveal several interesting insights that could potentially impact the short and long-term prospects of the company.
*Pros: *
Increasing Revenue: The total revenue of Medigene has been on an upward trend from €8,749,000 in 2020 to €10,463,000 in 2021 and further to €31,247,000 in 2022. This growth in revenue signifies that the company's products and services are gaining acceptance in the market, and it has been successful in expanding its customer base.
Comments
News
Medigene to Present at Upcoming Conferences
Planegg/Martinsried (19.02.2024)
Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell
Medigene announces indication selection for the clinical development of its TCR-T therapy program in solid tumors
Planegg/Martinsried (12.02.2024)
- Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program
Medigene AG: Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
Planegg/Martinsried 19.12.2023
Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell